ESLA

Announcements

Nothing here yet

Daily updates

• Estrella Immunopharma Reports Initial Safety Milestone in STARLIGHT-1 EB103 Expansion StudyOct 16, 2026
• Estrella Immunopharma Adds Fifth Site to Phase 1/2 STARLIGHT-1 Trial of EB103Oct 15, 2026

FDA designations

Nothing here yet

News

• Estrella Immunopharma treats the first patient with two EB103 infusions in the STARLIGHT-1 dose-expansion phaseOct 16, 2026
• Estrella Immunopharma adds Intermountain Health LDS Hospital as the fifth clinical site for its Phase 1/2 STARLIGHT-1 trial in B-cell non-Hodgkin lymphomaOct 14, 2026
• Estrella Immunopharma activates a second clinical site for the Phase 1/2 STARLIGHT-1 lymphoma trialJul 29, 2026
• Estrella advances STARLIGHT-1 trial to Phase II following positive DSMB recommendationDec 4, 2025
• Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial of EB103 with complete responses in all evaluable patientsNov 3, 2025